Linked Life Data

9872603

Source:http://linkedlifedata.com/resource/pubmed/id/9872603

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
1999-1-8
pubmed:abstractText
To evaluate the potential actions of vascular endothelial growth factor (VEGF) on capillary permeability and drug transport, tumorigenic human glioma cell lines were developed that expressed different levels of VEGF. Three human glioma cell lines (i.e. U373, SF126, SF188) were screened for VEGF under normoxic and hypoxic (i.e. induced by CoCl2) conditions by Western blot analysis. Subsequent to these results, sense and antisense VEGF164 cDNA transfections were conducted. It was found that parental SF188 (SF188/V-) and SF188/V+ (sense transfected) cells could serve as an appropriate in vivo model based on their divergent levels of VEGF expression. Media derived from SF188/V+ cells stimulated endothelial cell growth by 30-60%, and enhanced endothelial cell clonogenicity by 5-10-fold compared to SF188/V- or empty vector transfected cells. Nude rats implanted with either SF188/V- or SF188/V+ cells subcutaneously and intracerebrally formed tumors, with those derived from SF188/V+ cells growing at a faster rate. Immunohistochemistry analysis indicated that the expression of VEGF and number of capillaries (factor VIII assay) were approximately 3-fold greater in SF188/V+ tumors compared to SF188/V- tumors. Pharmacological assays, such as measurements of cytotoxicity and DNA adducts, in SF188/V- and SF188/V+ cells treated with carmustine or temozolomide were similar. Therefore, other than differences in VEGF expression and growth in vivo, SF188/V- and SF188/V+ cells possess a similar phenotype, and can serve as models to evaluate the influence of VEGF on drug transport.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0262-0898
pubmed:author
pubmed:issnType
Print
pubmed:volume
16
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
559-68
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed-meshheading:9872603-Animals, pubmed-meshheading:9872603-Antineoplastic Agents, Alkylating, pubmed-meshheading:9872603-Capillaries, pubmed-meshheading:9872603-Carmustine, pubmed-meshheading:9872603-Cell Hypoxia, pubmed-meshheading:9872603-DNA, Antisense, pubmed-meshheading:9872603-Dacarbazine, pubmed-meshheading:9872603-Endothelial Growth Factors, pubmed-meshheading:9872603-Genetic Vectors, pubmed-meshheading:9872603-Glioma, pubmed-meshheading:9872603-Humans, pubmed-meshheading:9872603-Lymphokines, pubmed-meshheading:9872603-Male, pubmed-meshheading:9872603-Neoplasm Proteins, pubmed-meshheading:9872603-Neovascularization, Pathologic, pubmed-meshheading:9872603-Rats, pubmed-meshheading:9872603-Rats, Nude, pubmed-meshheading:9872603-Transfection, pubmed-meshheading:9872603-Transplantation, Heterologous, pubmed-meshheading:9872603-Tumor Cells, Cultured, pubmed-meshheading:9872603-Vascular Endothelial Growth Factor A, pubmed-meshheading:9872603-Vascular Endothelial Growth Factors
pubmed:year
1998
pubmed:articleTitle
Modulation of angiogenesis by human glioma xenograft models that differentially express vascular endothelial growth factor.
pubmed:affiliation
Department Of Pharmacology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S.